1,622 results on '"Escudier, B."'
Search Results
2. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
3. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
4. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study
5. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
6. TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma
7. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
8. 23P Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
9. 184P Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study
10. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
11. How to report toxicity associated with targeted therapies?
12. International cancer seminars: a focus on kidney cancer
13. Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study
14. Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms
15. Nivolumab + ipilimumab (NIVO + IPI) adjuvant versus placebo dans le carcinome rénal localisé à haut risque de récidive après néphrectomie : résultats de l’étude de phase 3 randomisée Checkmate 914 (CM914)
16. 259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota
17. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
18. mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response
19. 1472P Biomarkers of the response in metastatic papillary renal cell carcinoma
20. 1459P Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)
21. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial
22. 1468P IO-synthesise RCC: Real-world outcomes of nivolumab in patients (pts) with previously treated advanced non-clear cell renal cell carcinoma (nccRCC) – A pooled analysis from France and Germany
23. 1460P IO-Synthesise RCC: Analysis of real-world (RW) health-related quality of life (HRQoL) outcomes with nivolumab for previously treated metastatic renal cell carcinoma (mRCC) using pooled data from France and Germany
24. Recommandations en onco-urologie 2013 du CCAFU: Cancer du rein
25. 1717TiP CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
26. 1703P Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
27. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
28. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers
29. Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology
30. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
31. Supplement to: Cabozantinib versus everolimus in advanced renal-cell carcinoma.
32. Supplement to: Nivolumab versus everolimus in advanced renal-cell carcinoma.
33. Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors
34. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
35. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
36. Cas cliniques de cancer du rein des JOUM 2010
37. Le point sur les différents types histologiques de cancer du rein et leur traitement spécifique
38. Who dies from prostate cancer?
39. Recommandations en Onco-Urologie 2010 : Cancer du rein
40. How to select targeted therapy in renal cell cancer
41. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network
42. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
43. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
44. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma
45. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
46. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
47. Incidence of brain metastases in renal cell carcinoma treated with sorafenib
48. Place du curage ganglionnaire dans la prise en charge des cancers du rein : revue de la littérature par le sous-comité rein du Comité de cancérologie de l’Association française d’urologie (CCAFU-rein)
49. Avancées et synthèse des derniers congrès : ASCO-GU, EAU, AUA, ASCO concernant la prise en charge médicale du cancer du rein localement avancé ou métastatique
50. 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.